Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded oral liquid containing enalapril maleate, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing enalapril are listed in tablet and solution forms.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Enalapril maleate is an ACE inhibitor blood pressure and heart medicine, taken by mouth, that a pharmacy may compound when a prescriber orders it.
Enalapril is an angiotensin-converting enzyme (ACE) inhibitor. It is a prodrug: the body converts it to enalaprilat, which blocks the enzyme that makes angiotensin II, a hormone that tightens blood vessels, so blood vessels relax and blood pressure falls. Manufactured products include Vasotec tablets, generic tablets, and Epaned and generic enalapril maleate oral solutions. Vasotec is indicated for high blood pressure, symptomatic heart failure and asymptomatic left ventricular dysfunction. Epaned is indicated for high blood pressure in adults and children older than one month, symptomatic heart failure and asymptomatic left ventricular dysfunction. A published Canadian stability study describes extemporaneously prepared enalapril maleate oral suspensions. A prescriber might order enalapril compounded in a strength, flavor or liquid form that is not manufactured, or without an ingredient a patient cannot tolerate. Compounded preparations are not FDA-approved and require a prescription.
Enalapril labels carry a boxed warning for fetal toxicity: drugs that act on the renin-angiotensin system can injure or kill a developing baby, so stop it as soon as pregnancy is detected and tell your prescriber. Do not use it if you have had angioedema (swelling of the face, lips, tongue or throat), including from another ACE inhibitor, or hereditary angioedema; if you have diabetes and take aliskiren; or within 36 hours of sacubitril/valsartan. Get emergency help for facial or throat swelling. Other warnings include low blood pressure, high potassium, kidney changes, rare liver injury and low white blood cell counts. Tell your prescriber about potassium supplements or salt substitutes, potassium-sparing diuretics, lithium and NSAIDs. A persistent dry cough has been reported with all ACE inhibitors; it goes away after the drug is stopped. LactMed says that needing enalapril is not a reason to stop breastfeeding, while the Epaned label advises not to breastfeed. Talk to your prescriber or pharmacist about side effects.
Enalapril is hydrolyzed, mainly by hepatic carboxylesterase 1 after OATP1B1 uptake, to enalaprilat, the active ACE inhibitor; enalaprilat itself is poorly absorbed orally. Per the Vasotec label, absorption is about 60 percent and unaffected by food, enalapril peaks in about one hour and enalaprilat in three to four hours, and the label gives an 11-hour half-life for accumulation of enalaprilat with multiple doses. Excretion is primarily renal, and the label reports higher enalaprilat levels once glomerular filtration is severely reduced. Labeled indications: hypertension, symptomatic heart failure and asymptomatic left ventricular dysfunction (Vasotec tablets, NDA; Epaned oral solution, NDA, which includes children older than one month). Epaned is not recommended in neonates, preterm infants below a corrected post-conceptual age of 44 weeks, or children with severely reduced glomerular filtration. Contraindications include ACE inhibitor-related, hereditary or idiopathic angioedema, aliskiren in diabetes, and neprilysin inhibitors. Angioedema risk rises with mTOR or neprilysin inhibitors; intestinal angioedema has been reported. Avoid dual RAS blockade. Monitor blood pressure, serum potassium and renal function, and white cell counts where indicated. Dosing is per prescriber.
Shake the bottle if your label says to. Measure each dose with the oral syringe or dosing cup the pharmacy gave you, never a kitchen spoon. Give the liquid slowly into the mouth. Rinse the syringe with water after each use. Call the pharmacy if you are unsure how to measure.
Storage depends on the vehicle. Water-based liquids with a preservative usually carry a USP <795> beyond-use date of up to 35 days; without a preservative they are kept refrigerated for up to 14 days. Oil-based (nonaqueous) oral liquids may carry up to 90 days. Your label states whether to refrigerate and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally
